About DIMA BIOTECH

DIMA Biotechnology provides preclinical R&D solutions for BioPharma, offering 5000+ validated mAbs and 300+ full-length multipass transmembrane proteins. Our platforms include Nanodisc, single B-cell mAb discovery, and mammalian cell display for antibody engineering – advancing drug development across GPCRs, ion channels, and other high-value difficult drug targets.

What We Showcase at AACR

01  DiMProTM Nanodisc Membrane Protein Platforms

  • Full-length GPCR proteins in native conformation
  • Ion channel and multi-pass membrane protein solutions
  • Stable and functional protein formats for drug discovery
  • 700+ Nanodisc proteins, with 300+ in stock

02  Ready-to-Test Lead mAbs for Therapeutic Targets

  • 5000+ Pre-validated IgG Sequences with Global Licensing Options, 500+ Druggable Targets

  • Zero Upfront, Zero Waiting, Zero Risk

  • Immediate Testing (Pre-clinical Validation Data PackageAvailable)
  • Functional Evaluation on Different ModalityPlatforms (CAR-T, ADC, BsAb, etc.)
  • Mammalian Cell Display Based Antibody Engineering Platform for lead mAbs Optimization(Humanization, Affinity Maturation, PTM Risk Removal)

Visit DIMA BIOTECH at AACR 2026

We welcome you to visit our booth (Booth #1704) for live discussions, product insights, and collaboration opportunities.

Resources

DIMA Highlights

Nanodisc cover

Nanodiscs

uploads-ADC Reagents_Cover

ADC Reagents

Nanodisc-Tx-mAb-discovery-poster-cover

Nanodisc used as Immunogen

QR code flyer cover

Digital Resources

DiNabody cover

DiNabody

Schedule a Meeting with Our Team

Secure a one-on-one meeting with our scientists and technical experts at AACR 2026.

Please share your details below:

Name
Please complete this required field.
Please complete this required field.
Please complete this required field.